CEL-SCI, Ergomed To Co-Develop Head And Neck Cancer Candidate As Potential HPV Treatment

SCI has signed a co-development and profit sharing agreement with Ergomed Clinical Research for CEL-SCI's investigational immunotherapy drug Multikine in HIV/HPV co-infected women with cervical dysplasia.

http://www.news-medical.net/news/20131015/CEL-SCI-Ergomed-To-Co-Develop-Head-And-Neck-Cancer-Candidate-As-Potential-HPV-Treatment.aspx